<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic bone marrow transplantation was performed in 10 patients with disseminated Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or poor-prognosis T-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received a cytoreduction regimen consisting of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, bis-chloro-<z:chebi fb="0" ids="35801">nitroso</z:chebi>-<z:chebi fb="20" ids="16199">urea</z:chebi>, and total-body irradiation </plain></SENT>
<SENT sid="2" pm="."><plain>Eight patients received marrow from HLA-matched sibling donors </plain></SENT>
<SENT sid="3" pm="."><plain>One patient received marrow from a parent donor and one patient died during initial cytoreduction and did not undergo total-body irradiation or marrow infusion </plain></SENT>
<SENT sid="4" pm="."><plain>Six patients had Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> stages III and IV at diagnosis, and three of the six are alive at 18, 28, and 73 months </plain></SENT>
<SENT sid="5" pm="."><plain>Four patients had T-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, stages III and IV at diagnosis, and two of the four are alive at 29 and 49 months </plain></SENT>
<SENT sid="6" pm="."><plain>Overall survival in the nine patients who underwent transplantation is 56 percent by life-table analysis </plain></SENT>
<SENT sid="7" pm="."><plain>Follow up for the surviving patients ranges from 18 to 73 months (median 29 months) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> five survivors are at home with unmaintained remissions </plain></SENT>
</text></document>